Cancer Immunotherapy Month is a series of educational and social events designed to raise awareness of this promising new cancer treatment. Check out some of the exciting activities we have planned for you!
Video: Cancer Immunotherapy Month Kick-Off
Dr. Jill O’Donnell-Tormey, CRI CEO and Director of Scientific Affairs, talks about what’s new in June for the 9th Annual Cancer Immunotherapy Month, including new patient information in Spanish.
Karen enrolled in a combination immunotherapy clinical trial for metastatic triple-negative breast cancer. In June 2020, her oncologist declared her a complete responder.
After Dale exhausted several treatment options for cutaneous squamous cell carcinoma, he enrolled in a clinical trial testing a PD-1 blocking antibody called cemiplimab. Almost immediately, his tumors began to disappear, and today, he has no evidence of disease.
National Cancer Survivors Day® is a celebration for those who have survived, an inspiration for those recently diagnosed, a gathering of support for families, and an outreach to the community.
After two years of intensive chemotherapy and two years in remission, Kristin's acute lymphoblastic leukemia returned. She enrolled in a phase one clinical trial of chimeric antigen receptor T cell (CAR T) therapy and finally achieved remission. Today, she encourages cancer patients to choose hope.
Diagnosed in 2016 with colorectal cancer, Michela is the first in three generations of her family to survive because of her immunotherapy treatment.
Learn about headline-grabbing research, practice-changing medicine, and new innovations in cancer immunotherapy from the world's largest oncology conference.
Join Generation Cure and raise awareness of the lifesaving potential of cancer immunotherapy. Make a sign, snap a selfie, and share how you are making a future immune to cancer with the hashtag #Immune2Cancer on Twitter, Instagram, or Facebook.
When he visited the hospital for a sharp pain in his side, Mike wasn't expecting a kidney cancer diagnosis. He consulted his family who advised him to get a second opinion and then enroll in a clinical trial combining two immunotherapies.
Over seven years ago, Kristin became one of the first patients to receive chimeric antigen receptor T cell (CAR T) therapy in an outpatient setting for acute lymphoblastic leukemia and achieve remission. Today, she is cancer-free and passionate about spreading hope
In this webinar for patients and caregivers, three CRI ImmunoAdvocates discuss redefining and navigating their lives after immunotherapy. Guest moderator Kristin Kleinhofer (leukemia) speaks to Gordon Levine (colorectal cancer) and Sunshine Pegues (lung cancer) about their unique cancer survivorship experiences, including the management of long-term side effects, continued self-advocacy and self-education, and their long-lasting relationships with their health care teams.
When oral cancer threatened to leave Rikki Rocket speechless, the drummer for Poison found and immunotherapy clinical trial. He has now been cancer-free for over four years.
CRI Postdoctoral Fellow Kamir Hiam-Galvez, Ph.D., of Stanford University, is using single-cell sequencing and lineage tracing to look at the gene regulatory networks that govern the state, fate, and behavior of helper T cells with the ultimate goal of characterizing the epigenetic landscape during their development.
When his partner, Kristin, confronted relapsed leukemia, Benny became her primary caregiver. Providing emotional and physical support for his partner was a challenging and deeply rewarding experience that he gratefully reflects on today.
CRI Postdoctoral Fellow Miguel Reina-Campos, Ph.D., of University of California, San Diego, is characterizing tissue-resident T cells and how they behave during infection to better understand how they might be manipulated against cancer. He will conduct a Reddit Ask Me Anything (AMA) session about cancer metabolism and the immune system on the CRI Reddit account.
Following diagnosis with stage 4 non-small cell lung cancer, Oswald began first-line treatment with a PD-L1 checkpoint immunotherapy. Today, he is cancer-free.